Pancreatic Cancer Research

ResearcherKyorin UniversityActive in the last 2 years

Yoshihiro Sakamoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7279-9702; OpenAlex author ID A5044489876. Sources: OpenAlex.

Their work

Papers
14 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
44
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper · 2026: 3 papers

Papers 14

  1. Molecular landscape of anaplastic transformation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/path.70136↗
  2. Diagnostic utility of MUC4 expression for distinguishing pancreatic ductal adenocarcinoma from extrahepatic cholangiocarcinoma and its clinicopathological sign… Co-author DOI 10.1016/j.humpath.2026.106137↗
  3. Prognostic impact of imaging tumor regression adjacent to major arteries after preoperative chemotherapy in surgical patients with advanced pancreatic cancer. Co-author DOI 10.1016/j.suronc.2026.102574↗
  4. Epigenetic evolution and clinicopathological implications of distinct DNA methylation profiles in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-025-13919-y↗
  5. Combination immunohistochemistry for CK5/6, p63, GATA6, and HNF4a predicts clinical outcome in treatment-naïve pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-024-65900-w↗
  6. Trends in the treatment of advanced pancreatic cancer. Last author DOI 10.5582/bst.2024.01156↗
  7. A Prospective Study of Neoadjuvant Gemcitabine Plus Nab-paclitaxel in Patients with Borderline-resectable Pancreatic Cancer. Co-author DOI 10.2169/internalmedicine.9504-22↗
  8. Trends in the surgical treatment for pancreatic cancer in the last 30 years. Last author DOI 10.5582/bst.2022.01250↗
  9. Trends in the treatment of pancreatic cancer in Japan. Last author DOI 10.5582/bst.2021.01103↗
  10. A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic … Co-author DOI 10.1007/s12032-018-1158-8↗
  11. Predictors of Postoperative Non-Chylous Massive Discharge after Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1159/000479341↗
  12. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer. Co-author DOI 10.18632/oncotarget.11129↗
  13. A R0 resection case of initially unresectable metastatic pancreatic cancer downstaged by FOLFIRINOX therapy. Co-author DOI 10.1097/mpa.0000000000000139↗
  14. Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer. First author DOI 10.1245/s10434-011-2020-9↗

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Junji Shibahara · 6 shared papers, 2023–2026 · strength 1.39
  2. Akimasa Hayashi · 5 shared papers, 2024–2026 · strength 1.23
  3. Ryota Matsuki · 5 shared papers, 2021–2026 · strength 1.02
  4. Takahiro Shibayama · 4 shared papers, 2024–2026 · strength 0.94
  5. Naohiro Okano · 4 shared papers, 2022–2026 · strength 0.78
  6. Hirokazu Momose · 3 shared papers, 2022–2026 · strength 0.69
  7. Keiichiro Kitahama · 2 shared papers, 2024–2025 · strength 0.42
  8. Christine A. Iacobuzio–Donahue · 2 shared papers, 2024–2026 · strength 0.40
  9. Fumio Nagashima · 2 shared papers, 2022–2023 · strength 0.31
  10. Saori Funakoshi · 1 shared paper, 2026 · strength 0.29
  11. Norihiro Kokudo · 4 shared papers, 2014–2018 · strength 0.24
  12. Kaloyan M. Tsanov · 1 shared paper, 2026 · strength 0.23
  13. Scott W. Lowe · 1 shared paper, 2026 · strength 0.23
  14. Wungki Park · 1 shared paper, 2026 · strength 0.23
  15. Eileen Mary O'Reilly · 1 shared paper, 2026 · strength 0.23
  16. Kiyoshi Hasegawa · 3 shared papers, 2016–2018 · strength 0.21
  17. Tadakazu Hisamatsu · 1 shared paper, 2024 · strength 0.17
  18. Shunsuke Watanabe · 1 shared paper, 2023 · strength 0.16
  19. Junji Furuse · 1 shared paper, 2023 · strength 0.16
  20. Masanori Sugiyama · 1 shared paper, 2023 · strength 0.16
  21. Hiroyuki Isayama · 3 shared papers, 2014–2018 · strength 0.15
  22. Kazuhiko Koike · 3 shared papers, 2014–2018 · strength 0.15
  23. Yousuke Nakai · 3 shared papers, 2014–2018 · strength 0.15
  24. Hideaki Ijichi · 2 shared papers, 2016–2018 · strength 0.11
  25. Kyoji Ito · 1 shared paper, 2018 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.